Search for dissertations about: "Jonathan Gilthorpe"

Showing result 1 - 5 of 6 swedish dissertations containing the words Jonathan Gilthorpe.

  1. 1. Studies of the Biology of Intrathecal Treatment in Progressive MS

    Author : Joakim Bergman; Anders Svenningsson; A. Tommy Bergenheim; Jonathan D. Gilthorpe; Joachim Burman; Magnus Andersson; Umeå universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Progressive Multiple Sclerosis; intrathecal treatment; Ommaya reservoir; anti-CD20 therapy; microdialysis; cerebrospinal fluid; CNS compartments; Progressiv Multipel Skleros; intratekal behandling; Ommaya reservoar; anti-CD20 terapi; mikrodialys; ryggmärgsvätska; sektioner i centrala nervsystemet; Neurology; neurologi;

    Abstract : Background: Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease, affecting the central nervous system (CNS). About 85% of afflicted present with a relapsing-remitting form of the disease (RRMS), for which a breakthrough in treatment was made in 2008 with rituximab, an antibody directed towards CD20, a surface antigen on B-cells. READ MORE

  2. 2. Using patient-derived cell models to investigate the role of misfolded SOD1 in ALS

    Author : Elin Forsgren; Jonathan Gilthorpe; Stefan Marklund; Peter Andersen; Thomas Brännström; Ulrika Nordström; Séverine Boillée; Umeå universitet; []
    Keywords : ALS; SOD1; patient-derived models; induced pluripotent stem cells; motor neurons; astrocytes; 20S proteasome low oxygen tension; misfolded SOD1; Neurology; neurologi;

    Abstract : Protein misfolding and aggregation underlie several neurodegenerative proteinopathies including amyotrophic lateral sclerosis (ALS). Superoxide dismutase 1 (SOD1) was the first gene found to be associated with familial ALS. READ MORE

  3. 3. SOD1 misfolding and aggregation in ALS : in the light of conformation-specific antibodies

    Author : Manuela Lehmann; Jonathan D. Gilthorpe; Stefan L. Marklund; Thomas Brännström; Ulrika Nordström; Elizabeth Fisher; Umeå universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; ALS; antibodies; SOD1; disordered SOD1; patient-derived models; low oxygen tension; Immunotherapy;

    Abstract : Mutations in the superoxide dismutase 1 (SOD1) gene are linked to the progressive neurodegenerative disease amyotrophic lateral sclerosis (ALS). ALS-associated mutations affect the stability of the SOD1 protein and promote its unfolding. As a consequence, disordered SOD1 species can misfold and accumulate into insoluble aggregates. READ MORE

  4. 4. The release of histone proteins from cells via extracellular vesicles

    Author : Uma Muthukrishnan; Jonathan Gilthorpe; Miles Trupp; Umeå universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; NATURAL SCIENCES; MEDICAL AND HEALTH SCIENCES; Histone; extracellular vesicles; exosomes; extracellular histones extracellular DNA; cellular stress; proteomics; ESCRT complex; Lrrn1; mid-hindbrain organizer; ovarian cancer; ascites;

    Abstract : Histones are chromatin-associated proteins localized to the nucleus. However, extracellular histones are present in biofluids from healthy individuals and become elevated under disease conditions, such as neurodegeneration and cancer. READ MORE

  5. 5. Brain parenchymal fraction in healthy individuals and in clinical follow-up of multiple sclerosis

    Author : Mattias Vågberg; Anders Svenningsson; Richard Birgander; Jonathan Gilthorpe; Anne-Marie Landtblom; Umeå universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Brain parenchymal fraction; Neurofilament light; Glial fibrillary acidic protein; Brain atrophy; Multiple Sclerosis; Clinical follow-up;

    Abstract : Background Multiple sclerosis (MS) is an autoimmune disease characterised by inflammatory damage to the central nervous system (CNS). Accumulated CNS injury can be quantified as brain atrophy, definable as a reduction in brain parenchymal fraction (BPF). BPF correlate with disability in MS and is used routinely as an endpoint in clinical trials. READ MORE